Table 1 Patient characteristics
Number of patients | ||
|---|---|---|
(N = 318) | % | |
Age | 64 (36–86) | |
Male/Female ratio | 229/89 | 72/28 |
WHO 0 | 129 | 44 |
1 | 151 | 53 |
2 | 10 | 3 |
Unknown | 28 | |
Histology | ||
Adenocarcinoma | 68 | 21.4 |
Squamous cell | 157 | 49.4 |
NSCLC-NOS | 93 | 29.2 |
Smokers | ||
None | 9 | 3 |
Current | 163 | 51 |
Former | 109 | 34 |
Unknown | 37 | 12 |
Induction treatment | ||
Cisplatin/gemcitabine | 242 | 76 |
Carboplatin/gemcitabine | 42 | 13 |
Platinum/pemetrexed | 4 | 1 |
Other | 5 | 2 |
No induction | 25 | 8 |
Radiotherapy dose received | ||
30-59 Gy | 34 | 11 |
60 Gy | 284 | 89 |
>60 Gy | 0 | 0 |
During chemoradiotherapy: | ||
Received 5 gemcitabine cycles | ||
and 60 Gy | 244 | 76 |
Received 1–4 gemcitabine cycles | ||
and/or received less | ||
then 60 Gy | 74 | 24 |